Drug Profile
Repaglinide
Alternative Names: AGEE 623; AGEE 623 ZW; GlucoNorm; NN 623; NovoNorm; Prandin; SMP 508; SurepostLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Novo Nordisk; Sumitomo Pharma
- Class Antihyperglycaemics; Carbamates; Piperidines; Small molecules
- Mechanism of Action Insulinotropin agonists; Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 18 Nov 2014 Launched for Type-2 diabetes mellitus (Combination therapy) in Japan (PO)
- 18 Nov 2014 Sumitomo Dainippon Pharma receives approval in Japan for partial change of the approved indications to include the use of repaglinide in combination with any oral hypoglycaemic agents, except with sulfonylurea and insulin formulations